|
 US Genomics (USG) is pioneering single molecule biology technologies for diagnostics and biodefense applications by combining advanced microfluidics, optical engineering, and novel labeling strategies. Using its DNA mapping technology, the Company is developing sophisticated biological sensors for the detection and identification of pathogens and biomarkers in the air and other biologically relevant materials. The Company’s biodefense focus on airborne pathogens has been funded in part by contracts from the U.S. Department of Homeland Security Science and Technology Directorate. U.S. Genomics’ portfolio of products will further a greater understanding of genetics and disease pathways leading to more effective use of therapeutics, and a range of diagnostics, and biodefense applications. For more information, please visit www.usgenomics.com
 Antisoma plc [LSE:ASM; USOTC: ATSMY] Antisoma is a London Stock Exchange-listed biopharmaceutical company that develops novel products for the treatment of cancer and has a diverse portfolio of drugs in development. The Company was founded in 1988 has operations in the UK and the US. Please visit www.antisoma.com for further information. Antisoma plc acquired Xanthus Pharmaceuticals in June 2008. |
|
       |
